Biomedicines
The Differences Between Dopamine Agonist-Resistant and -Non-Resistant Prolactinomas: Are There Any Predictors of a Good Response?
Maria Komisarz-Calik, Anna Bogusławska, Aleksandra Gamrat-Żmuda, Mari Minasyan, Beata Piwońska-Solska, Jacek Kunicki, Grzegorz Zieliński, Agata Faron-Górecka, Alicja Hubalewska-Dydejczyk, Aleksandra Gilis-Januszewska
Published: 202610.3390/biomedicines14010234
Abstract
Background/Objectives: Dopamine agonists (DAs) are the first-line therapy for prolactinomas; however, a subset of patients exhibits resistance or incomplete response. Methods: This retrospective study included 85 of 125 eligible consecutive patients…
Preview only. Read the full abstract at the source